Last reviewed · How we verify
positive comparative patch
At a glance
| Generic name | positive comparative patch |
|---|---|
| Also known as | topical patch |
| Sponsor | Frontier Biotechnologies Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparative Efficacy of Intra-articular vs. MRI-guided Extra-articular Dextrose Injections in Knee Osteoarthritis Management (NA)
- Effect of Different Remineralizing Agents on White Spot Lesions Treatment in Children (NA)
- the Remineralizing Self-Assembling Peptide P11-4, 2% Arginine Enriched Sodium Fluoride and Functionalized Tri Calcium Phosphate Fluoride White Spot Lesions (NA)
- Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT (PHASE2)
- Tolerability, Safety and Pharmacokinetics of a Topical AB001 Patch in Healthy Subjects (PHASE1)
- Detection and Localization of Carcinoma Using High Resolution Transrectal Imaging - Proof of Concept Study (NA)
- Comparative Safety Study of New Sinecort Formulation Versus Positive Control (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- positive comparative patch CI brief — competitive landscape report
- positive comparative patch updates RSS · CI watch RSS
- Frontier Biotechnologies Inc. portfolio CI